 Gregory Kinney
Concepts (384)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 50 | 2023 | 1401 | 5.130 |
Why?
| | Coronary Artery Disease | 26 | 2021 | 706 | 1.830 |
Why?
| | Tomography, X-Ray Computed | 40 | 2022 | 2519 | 1.800 |
Why?
| | Diabetes Mellitus, Type 1 | 37 | 2022 | 3347 | 1.770 |
Why?
| | Smokers | 15 | 2023 | 173 | 1.570 |
Why?
| | Smoking | 23 | 2023 | 1603 | 1.430 |
Why?
| | Pulmonary Emphysema | 11 | 2023 | 365 | 1.220 |
Why?
| | Bronchiectasis | 7 | 2023 | 104 | 1.170 |
Why?
| | Forced Expiratory Volume | 22 | 2023 | 613 | 1.140 |
Why?
| | Calcinosis | 17 | 2015 | 292 | 1.050 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 589 | 0.970 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 170 | 0.940 |
Why?
| | Hyperlipidemias | 2 | 2023 | 136 | 0.930 |
Why?
| | Cannabis | 7 | 2023 | 371 | 0.890 |
Why?
| | Dronabinol | 3 | 2021 | 121 | 0.880 |
Why?
| | Marijuana Smoking | 3 | 2022 | 226 | 0.880 |
Why?
| | Lung | 19 | 2023 | 3767 | 0.850 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 272 | 0.760 |
Why?
| | Volatilization | 1 | 2019 | 64 | 0.740 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 81 | 0.720 |
Why?
| | Cannabinoids | 4 | 2023 | 120 | 0.690 |
Why?
| | Middle Aged | 78 | 2023 | 28961 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2167 | 0.620 |
Why?
| | Coronary Vessels | 7 | 2021 | 250 | 0.620 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1812 | 0.610 |
Why?
| | Marijuana Abuse | 1 | 2019 | 208 | 0.610 |
Why?
| | Air Pollution | 1 | 2019 | 219 | 0.590 |
Why?
| | Risk Factors | 34 | 2023 | 9419 | 0.580 |
Why?
| | Female | 95 | 2023 | 63903 | 0.570 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 21 | 0.550 |
Why?
| | Male | 88 | 2023 | 60475 | 0.540 |
Why?
| | Vascular Calcification | 5 | 2019 | 125 | 0.540 |
Why?
| | Humans | 116 | 2023 | 121869 | 0.540 |
Why?
| | Disease Progression | 24 | 2021 | 2582 | 0.530 |
Why?
| | Spirometry | 12 | 2023 | 319 | 0.520 |
Why?
| | Risk Assessment | 8 | 2019 | 3248 | 0.510 |
Why?
| | Aged | 37 | 2022 | 20705 | 0.470 |
Why?
| | Cohort Studies | 27 | 2023 | 5300 | 0.450 |
Why?
| | Prospective Studies | 25 | 2023 | 6629 | 0.450 |
Why?
| | Coronary Disease | 7 | 2010 | 396 | 0.400 |
Why?
| | Emphysema | 2 | 2023 | 138 | 0.380 |
Why?
| | Pulmonary Artery | 4 | 2022 | 1084 | 0.370 |
Why?
| | Adult | 48 | 2023 | 32683 | 0.370 |
Why?
| | Depression | 4 | 2022 | 1201 | 0.350 |
Why?
| | Lipoproteins | 3 | 2016 | 161 | 0.350 |
Why?
| | Prevalence | 12 | 2023 | 2444 | 0.350 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 20 | 0.340 |
Why?
| | Albuminuria | 4 | 2016 | 184 | 0.340 |
Why?
| | Calcium | 7 | 2018 | 1207 | 0.320 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2876 | 0.320 |
Why?
| | Metformin | 2 | 2021 | 301 | 0.310 |
Why?
| | Marijuana Use | 2 | 2021 | 153 | 0.310 |
Why?
| | Case-Control Studies | 14 | 2019 | 3314 | 0.300 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 415 | 0.290 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1965 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 7 | 2023 | 2377 | 0.280 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 145 | 0.280 |
Why?
| | Quality of Life | 4 | 2021 | 2453 | 0.280 |
Why?
| | Vital Capacity | 5 | 2023 | 287 | 0.280 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1190 | 0.280 |
Why?
| | Cause of Death | 2 | 2018 | 400 | 0.270 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 67 | 0.270 |
Why?
| | Antidepressive Agents | 3 | 2019 | 201 | 0.270 |
Why?
| | Bronchi | 2 | 2016 | 249 | 0.260 |
Why?
| | Biomarkers | 11 | 2022 | 3652 | 0.260 |
Why?
| | Body Mass Index | 10 | 2022 | 2174 | 0.260 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 227 | 0.250 |
Why?
| | Renal Insufficiency | 2 | 2016 | 145 | 0.250 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 366 | 0.250 |
Why?
| | Symptom Flare Up | 2 | 2021 | 39 | 0.240 |
Why?
| | Multimorbidity | 1 | 2023 | 29 | 0.230 |
Why?
| | Logistic Models | 12 | 2017 | 2037 | 0.230 |
Why?
| | Fibrinogen | 3 | 2014 | 167 | 0.230 |
Why?
| | Propofol | 2 | 2021 | 48 | 0.230 |
Why?
| | Young Adult | 14 | 2022 | 11223 | 0.230 |
Why?
| | Limit of Detection | 2 | 2019 | 60 | 0.220 |
Why?
| | Aged, 80 and over | 9 | 2022 | 6974 | 0.220 |
Why?
| | Atherosclerosis | 3 | 2019 | 348 | 0.220 |
Why?
| | Adiponectin | 4 | 2016 | 231 | 0.220 |
Why?
| | Population Health | 1 | 2023 | 47 | 0.220 |
Why?
| | Cross-Sectional Studies | 12 | 2023 | 4713 | 0.220 |
Why?
| | Umbilical Cord | 2 | 2021 | 79 | 0.220 |
Why?
| | Follow-Up Studies | 10 | 2022 | 4883 | 0.220 |
Why?
| | Cannabidiol | 1 | 2023 | 57 | 0.220 |
Why?
| | Ketosis | 1 | 2022 | 13 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 73 | 0.210 |
Why?
| | Cystatin C | 3 | 2011 | 67 | 0.210 |
Why?
| | Cholesterol | 4 | 2011 | 376 | 0.210 |
Why?
| | Hallucinogens | 1 | 2023 | 74 | 0.210 |
Why?
| | Protective Agents | 1 | 2021 | 41 | 0.210 |
Why?
| | Sarcopenia | 1 | 2022 | 68 | 0.210 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 73 | 0.210 |
Why?
| | Hand Strength | 2 | 2022 | 100 | 0.200 |
Why?
| | Self Report | 3 | 2021 | 740 | 0.200 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 247 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2014 | 362 | 0.190 |
Why?
| | Genome-Wide Association Study | 5 | 2023 | 1355 | 0.190 |
Why?
| | Longitudinal Studies | 7 | 2023 | 2652 | 0.190 |
Why?
| | Muscular Atrophy | 1 | 2021 | 85 | 0.190 |
Why?
| | Delirium | 1 | 2021 | 69 | 0.190 |
Why?
| | Hepatitis C | 1 | 2023 | 230 | 0.190 |
Why?
| | 2-Propanol | 1 | 2019 | 22 | 0.190 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.180 |
Why?
| | Foam Cells | 1 | 2019 | 16 | 0.180 |
Why?
| | Hyperostosis | 1 | 2019 | 7 | 0.180 |
Why?
| | Calibration | 1 | 2019 | 140 | 0.180 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 289 | 0.180 |
Why?
| | Osteoporosis | 1 | 2022 | 242 | 0.180 |
Why?
| | Airway Obstruction | 1 | 2021 | 169 | 0.180 |
Why?
| | Genetic Markers | 2 | 2019 | 371 | 0.180 |
Why?
| | Carbon Monoxide | 1 | 2019 | 69 | 0.180 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 177 | 0.180 |
Why?
| | Blood Glucose | 6 | 2022 | 1949 | 0.180 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 44 | 0.170 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 445 | 0.170 |
Why?
| | Surface Properties | 1 | 2019 | 411 | 0.170 |
Why?
| | Drug Overdose | 1 | 2022 | 283 | 0.170 |
Why?
| | Diabetes Complications | 2 | 2010 | 222 | 0.170 |
Why?
| | Adipose Tissue | 2 | 2017 | 632 | 0.160 |
Why?
| | United States | 9 | 2022 | 13209 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 154 | 0.160 |
Why?
| | Insulin Resistance | 4 | 2017 | 1174 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2019 | 149 | 0.160 |
Why?
| | Heart Ventricles | 2 | 2020 | 748 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 210 | 0.160 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 298 | 0.160 |
Why?
| | Organ Size | 4 | 2021 | 482 | 0.160 |
Why?
| | Urine | 1 | 2017 | 64 | 0.160 |
Why?
| | HIV Infections | 2 | 2023 | 2506 | 0.160 |
Why?
| | Environmental Monitoring | 1 | 2019 | 309 | 0.160 |
Why?
| | Population Surveillance | 1 | 2021 | 439 | 0.160 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 664 | 0.150 |
Why?
| | Linear Models | 6 | 2019 | 886 | 0.150 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 30 | 0.150 |
Why?
| | Chronic Disease | 1 | 2023 | 1655 | 0.150 |
Why?
| | Phenotype | 4 | 2019 | 3078 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 486 | 0.150 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 30 | 0.150 |
Why?
| | Prenatal Care | 1 | 2019 | 251 | 0.150 |
Why?
| | Obesity | 4 | 2022 | 2802 | 0.140 |
Why?
| | Machine Learning | 1 | 2019 | 344 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 873 | 0.140 |
Why?
| | Blood Pressure | 5 | 2023 | 1717 | 0.140 |
Why?
| | Plasma | 1 | 2017 | 228 | 0.140 |
Why?
| | Aortography | 1 | 2015 | 54 | 0.140 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 15 | 0.140 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 957 | 0.130 |
Why?
| | Dyspnea | 3 | 2023 | 213 | 0.130 |
Why?
| | Comorbidity | 5 | 2021 | 1633 | 0.130 |
Why?
| | Respiratory System | 1 | 2016 | 145 | 0.130 |
Why?
| | Exercise Tolerance | 3 | 2023 | 254 | 0.130 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1574 | 0.130 |
Why?
| | Dexmedetomidine | 1 | 2015 | 58 | 0.130 |
Why?
| | Periodontal Diseases | 1 | 2015 | 83 | 0.130 |
Why?
| | Adiposity | 2 | 2022 | 505 | 0.130 |
Why?
| | Respiratory Muscles | 1 | 2014 | 33 | 0.130 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 159 | 0.130 |
Why?
| | Evoked Potentials | 1 | 2015 | 140 | 0.130 |
Why?
| | Regression Analysis | 5 | 2017 | 1049 | 0.130 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 57 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2107 | 0.120 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 916 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 91 | 0.120 |
Why?
| | Health Status | 2 | 2022 | 797 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 461 | 0.120 |
Why?
| | Spine | 1 | 2015 | 145 | 0.120 |
Why?
| | Body Composition | 4 | 2021 | 721 | 0.120 |
Why?
| | Heart | 1 | 2017 | 671 | 0.120 |
Why?
| | Aorta | 1 | 2015 | 374 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 882 | 0.110 |
Why?
| | Sex Distribution | 5 | 2014 | 374 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 219 | 0.110 |
Why?
| | Colorado | 6 | 2021 | 4344 | 0.110 |
Why?
| | Haptoglobins | 1 | 2011 | 30 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 501 | 0.110 |
Why?
| | Artificial Intelligence | 2 | 2023 | 147 | 0.110 |
Why?
| | Triglycerides | 2 | 2011 | 523 | 0.100 |
Why?
| | Blood Vessels | 1 | 2013 | 191 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1956 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 309 | 0.100 |
Why?
| | Adolescent | 6 | 2022 | 19126 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1845 | 0.100 |
Why?
| | Alcohol Drinking | 2 | 2009 | 692 | 0.100 |
Why?
| | Walk Test | 2 | 2021 | 57 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2021 | 13063 | 0.090 |
Why?
| | Coma | 1 | 2009 | 37 | 0.090 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 10 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 435 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2005 | 720 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 515 | 0.090 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 29 | 0.090 |
Why?
| | Facial Nerve | 1 | 2009 | 33 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2010 | 94 | 0.090 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 47 | 0.090 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 16 | 0.090 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 32 | 0.090 |
Why?
| | Airway Remodeling | 2 | 2021 | 61 | 0.090 |
Why?
| | Hypertension | 5 | 2015 | 1241 | 0.090 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 30 | 0.090 |
Why?
| | Kidney | 1 | 2016 | 1247 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1871 | 0.090 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 12 | 0.090 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 82 | 0.090 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2999 | 0.080 |
Why?
| | Proteinuria | 1 | 2009 | 92 | 0.080 |
Why?
| | Odds Ratio | 4 | 2014 | 1052 | 0.080 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 253 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2019 | 4922 | 0.080 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.080 |
Why?
| | Sex Factors | 4 | 2020 | 1898 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| | Cystatins | 1 | 2007 | 6 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 2130 | 0.080 |
Why?
| | Coronary Angiography | 2 | 2014 | 346 | 0.080 |
Why?
| | Face | 1 | 2009 | 184 | 0.080 |
Why?
| | Radiography | 3 | 2016 | 885 | 0.080 |
Why?
| | Inflammation | 2 | 2021 | 2522 | 0.080 |
Why?
| | Life Style | 1 | 2009 | 436 | 0.080 |
Why?
| | Uric Acid | 1 | 2010 | 354 | 0.080 |
Why?
| | Prognosis | 4 | 2021 | 3603 | 0.080 |
Why?
| | Mortality | 2 | 2019 | 325 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 788 | 0.070 |
Why?
| | Time Factors | 6 | 2015 | 6889 | 0.070 |
Why?
| | Apolipoproteins A | 1 | 2006 | 20 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.070 |
Why?
| | Contraception | 1 | 2008 | 127 | 0.070 |
Why?
| | Apolipoproteins C | 1 | 2006 | 6 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 339 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2520 | 0.070 |
Why?
| | Propensity Score | 2 | 2019 | 250 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 427 | 0.070 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 68 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2019 | 512 | 0.070 |
Why?
| | Internationality | 2 | 2017 | 160 | 0.070 |
Why?
| | Receptors, IgG | 1 | 2005 | 67 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 403 | 0.070 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 564 | 0.070 |
Why?
| | Pregnancy | 3 | 2023 | 5663 | 0.070 |
Why?
| | Abdominal Wall | 1 | 2004 | 28 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 469 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 13 | 0.060 |
Why?
| | Haplotypes | 1 | 2006 | 486 | 0.060 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 641 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 319 | 0.060 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 195 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 371 | 0.060 |
Why?
| | Insulin | 3 | 2022 | 2156 | 0.060 |
Why?
| | Antigens, CD | 1 | 2005 | 468 | 0.060 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 136 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 400 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2023 | 140 | 0.050 |
Why?
| | Genotype | 3 | 2018 | 1952 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 172 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 300 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 341 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 44 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 25 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1356 | 0.050 |
Why?
| | Reaction Time | 2 | 2015 | 441 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 97 | 0.050 |
Why?
| | Reference Values | 3 | 2010 | 804 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 236 | 0.050 |
Why?
| | Plethysmography | 1 | 2021 | 128 | 0.050 |
Why?
| | Child, Preschool | 3 | 2023 | 9776 | 0.050 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 42 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 65 | 0.050 |
Why?
| | Anesthesia, General | 1 | 2021 | 51 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2021 | 139 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 960 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 350 | 0.050 |
Why?
| | Cigarette Smoking | 1 | 2021 | 89 | 0.050 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 500 | 0.050 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9654 | 0.050 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.050 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2021 | 182 | 0.050 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 13 | 0.050 |
Why?
| | Lipids | 2 | 2017 | 607 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2019 | 50 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 29 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 456 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 44 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 663 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 595 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1383 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 284 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 477 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 453 | 0.040 |
Why?
| | Europe | 1 | 2019 | 368 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 61 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1866 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 21 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1003 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 79 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 101 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 525 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2016 | 39 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 298 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 641 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 105 | 0.040 |
Why?
| | Bronchial Arteries | 1 | 2016 | 13 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 962 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2017 | 66 | 0.040 |
Why?
| | Causality | 1 | 2017 | 116 | 0.040 |
Why?
| | RNA | 1 | 2023 | 860 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 901 | 0.040 |
Why?
| | Area Under Curve | 1 | 2016 | 308 | 0.040 |
Why?
| | Urban Population | 1 | 2019 | 433 | 0.040 |
Why?
| | Cough | 1 | 2016 | 108 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 503 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 38 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 33 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 34 | 0.030 |
Why?
| | Automation | 1 | 2015 | 79 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 328 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 285 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 258 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 496 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1083 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 700 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 39 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 251 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1067 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 167 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1316 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15621 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 94 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 509 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 164 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 996 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2727 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 176 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2017 | 412 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5054 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 338 | 0.030 |
Why?
| | Exercise Test | 1 | 2014 | 617 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2015 | 1720 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 526 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 26 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 111 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 582 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 15 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 94 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 129 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 316 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 143 | 0.020 |
Why?
| | Animals | 2 | 2021 | 34134 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 348 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 80 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3173 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1618 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 478 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 345 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 12 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 20 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 479 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 65 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 150 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 58 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 344 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 361 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 716 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 286 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 32 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1873 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 98 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 33 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 386 | 0.020 |
Why?
| | Anthropometry | 1 | 2004 | 207 | 0.020 |
Why?
| | Alleles | 1 | 2006 | 850 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 625 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2241 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1108 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1211 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 325 | 0.010 |
Why?
| | Risk | 1 | 2003 | 925 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1194 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1399 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2322 | 0.010 |
Why?
| | Child | 1 | 2017 | 19282 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1033 | 0.010 |
Why?
| | Infant | 1 | 2009 | 8440 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|